Bitte aktiviere Javascript und schalte etwaige Werbeblocker ab

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-News: freenet AG welcomes ISS' recommendation that Sunrise shareholders should vote AGAINST the proposed acquisition of UPC Switzerland : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24058/375px-Freenet_AG_Logo.svg.png

DGAP-News: freenet AG welcomes ISS' recommendation that Sunrise shareholders should vote AGAINST the proposed acquisition of UPC Switzerland

DGAP-News: freenet AG welcomes ISS' recommendation that Sunrise shareholders should vote AGAINST the proposed acquisition of UPC Switzerland

0

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS UNTERZEICHNEN LIZENZVEREINBARUNG FÜR EIN BIOSIMILAR-PROGRAMM: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS UNTERZEICHNEN LIZENZVEREINBARUNG FÜR EIN BIOSIMILAR-PROGRAMM

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS UNTERZEICHNEN LIZENZVEREINBARUNG FÜR EIN BIOSIMILAR-PROGRAMM

0

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS SIGN LICENSING DEAL FOR A BIOSIMILAR ASSET: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS SIGN LICENSING DEAL FOR A BIOSIMILAR ASSET

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS SIGN LICENSING DEAL FOR A BIOSIMILAR ASSET

0

DGAP-News: EVOTEC UND CELMATIX GEHEN STRATEGISCHE ZUSAMMENARBEIT EIN: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC UND CELMATIX GEHEN STRATEGISCHE ZUSAMMENARBEIT EIN

DGAP-News: EVOTEC UND CELMATIX GEHEN STRATEGISCHE ZUSAMMENARBEIT EIN

0

DGAP-News: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION

DGAP-News: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION

0

DGAP-News: freenet AG: Clarification of voting behaviour in the Board of Directors of the Sunrise: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24058/375px-Freenet_AG_Logo.svg.png

DGAP-News: freenet AG: Clarification of voting behaviour in the Board of Directors of the Sunrise

DGAP-News: freenet AG: Clarification of voting behaviour in the Board of Directors of the Sunrise

0

DGAP-News: freenet AG: Clarification of voting behaviour in the Board of Directors of the Sunrise: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24058/375px-Freenet_AG_Logo.svg.png

DGAP-News: freenet AG: Clarification of voting behaviour in the Board of Directors of the Sunrise

DGAP-News: freenet AG: Clarification of voting behaviour in the Board of Directors of the Sunrise

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt CEO Führungswechsel bekannt: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt CEO Führungswechsel bekannt

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt CEO Führungswechsel bekannt

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt Abweichung von den vorläufigen Umsatzzahlen für das dritte Quartal 2019 bekannt : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt Abweichung von den vorläufigen Umsatzzahlen für das dritte Quartal 2019 bekannt

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt Abweichung von den vorläufigen Umsatzzahlen für das dritte Quartal 2019 bekannt

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an

DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio

0

EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies

EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies

0

EQS-News: Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)

EQS-News: Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)

0

EQS-Adhoc: VARTA AG: VARTA AG announces an amendment to the restructuring concept and commercial agreement on bridge financing

EQS-Adhoc: VARTA AG: VARTA AG announces an amendment to the restructuring concept and commercial agreement on bridge financing

0

EQS-News: Evotec announces change in Management Board : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec announces change in Management Board

EQS-News: Evotec announces change in Management Board

0

EQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

EQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

0

EQS-News: Final contract signed: Vodafone and 1&1 kick off National Roaming Partnership: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24057/Drillisch_AG_Logo.svg.png

EQS-News: Final contract signed: Vodafone and 1&1 kick off National Roaming Partnership

EQS-News: Final contract signed: Vodafone and 1&1 kick off National Roaming Partnership

0

EQS-News: VARTA AG reaches agreement with financial creditors and strategic investors on a restructuring plan and creates the basis for a sustainable business perspective

EQS-News: VARTA AG reaches agreement with financial creditors and strategic investors on a restructuring plan and creates the basis for a sustainable business perspective

0

EQS-Adhoc: VARTA AG: VARTA AG announces commercial agreement on restructuring concept

EQS-Adhoc: VARTA AG: VARTA AG announces commercial agreement on restructuring concept

0

EQS-News: Nagarro posts 6.3% YoY revenue growth in constant currency in H1 2024 despite global macroeconomic challenges: https://upload.wikimedia.org/wikipedia/commons/0/0a/Nagarro_Horizontal_Light_400x100px_300dpi.png

EQS-News: Nagarro posts 6.3% YoY revenue growth in constant currency in H1 2024 despite global macroeconomic challenges

EQS-News: Nagarro posts 6.3% YoY revenue growth in constant currency in H1 2024 despite global macroeconomic challenges

0

EQS-News: Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths

EQS-News: Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths

0

EQS-News: CANCOM: CANCOM Group holds its own in a challenging market environment: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24051/375px-PLAN._BUILT._PERFORM..png

EQS-News: CANCOM: CANCOM Group holds its own in a challenging market environment

EQS-News: CANCOM: CANCOM Group holds its own in a challenging market environment

0

EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb

EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb

0